Research hints that medications like Zepbound and Wegovy could provide new ways to treat opioid and alcohol abuse.

Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too.

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people with substance use disorders. These medications, often prescribed for diabetes and weight issues,

Weight-loss drugs like Ozempic and Mounjaro, which also treat diabetes, may help users battling drug and alcohol abuse as well. A study published in the Addiction medical journal Wednesday showed roughy 1.